International forskning

The Effect of Cannabidiol 3% on Neuropsychiatric Symptoms in Dementia – Six-Month Follow-Up


Alexandri F | Papadopoulou L | Tsolaki A | Papantoniou G | Athanasiadis L | Tsolaki M

Neurosciences and Neurodegenerative Diseases, Postgraduate Course, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Greece.; Greek Association of Alzheimer’s Disease and Related Disorders (Alzheimer Hellas), Thessaloniki, Greece.; 1st Department of Neurology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Greece.; Department of Early Childhood Education, Faculty of Education Science, University of Ioannina, Ioannina, Greece.; 1st Department of Psychiatry, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Greece.; Neurosciences and Neurodegenerative Diseases, Postgraduate Course, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Greece.; Greek Association of Alzheimer’s Disease and Related Disorders (Alzheimer Hellas), Thessaloniki, Greece.; 1st Department of Neurology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, Makedonia, Greece.

Affiliationer

Objectives

To investigate the beneficial outcomes of giving cannabidiol (CBD) 3% over a six-month period in the BPSD, the management of which is a crucial issue for everyday clinical praxis and to compare the progress in BPSD of patients who receive Cannabidiol 3% with those who follow usual medical treatment (UMT) in everyday clinical praxis.

Methods

A total of 20 PwD with severe BPSD were recruited from the database of Alzheimer Hellas with NPI score >30. Ten of them were assigned to UMT, while ten were assigned to a six-month treatment with CBD drops. The follow-up assessment was performed with NPI, both clinically and by structured telephone interview.

Results

The follow-up assessment with NPI showed significant improvement of the BPSD in all our patients who received CBD, and no or limited improvement in the second group, regardless of the underlying neuropathology of dementia.

Conclusions

We suggest that CBD may be a more effective and safe choice for managing BPSD than the typical intervention. Future large randomized clinical trials are needed to re-assure these findings.